In CRC, biomarkers such as RAS (KRAS, NRAS), BRAFV600E, microsatellite instability (MSI)/mismatch repair, and human epidermal growth factor receptor 2 (HER2) can significantly influence treatment selection, enabling the development of tailored therapeutic strategies based on specific genetic mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.